Zymeworks Inc. · NASDAQ:ZYME
Zymeworks — ESMO-Asia 2019
8 slides from Zymeworks's conference presentation, Nov 22, 2019
Slide 1: Safety, Anti-Tumor Activity, and Biomarker Results of ZW25 in HER2-Expressing Solid Tumors
Safety, Anti-Tumor Activity, and Biomarker Results of the HER2-Targeted Bispecific Antibody ZW25 in HER2-Expressing Solid Tumors D.-Y. Oh1, E. Hamilton2, D. Hanna3, M. Beeram4, K.-W. Lee5, Y.-K. Kang6, J. Chaves7, J.-Y. Lee8, R. Goodwin9, C. Vaklavas10, S.-Y. Rha11, E. Elimova12, J. Mayordomo13, C.
Slide 2: Disclosure Information
Disclosure Information Dr. Oh reports personal fees from Genentech/Roche, AstraZeneca, Novartis, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, grants from AstraZeneca, Novartis, Array, Eli Lilly, outside the submitted work. 2
Slide 3: ZW25, A HER2-Targeted Bispecific Antibody in HER2-expressing Cancers
ZW25, A HER2-Targeted Bispecific Antibody in HER2-expressing Cancers • ZW25 is a novel HER2-targeted bispecific antibody that binds to the ECD4 and ECD2 domains of HER2 • The unique biparatopic binding configuration of ZW25 leads to multiple MOAs, including increased receptor binding, clustering and
Slide 4: Patient Characteristics
Patient Characteristics Median of 3 prior systemic regimens, including HER2-targeted therapies BTC CRC GEA Other Total (N=11) (N=14) (N=28) (N=16) (N=69) Baseline ECOG 0 (n, [%]) 2 (18) 5 (36) 2 (7) 2 (13) 11 (16) 1 (n, [%]) 9 (82) 9 (64) 26 (93) 14 (88) 58 (84) Median prior systemic regimens (range
Slide 5: Anti-Tumor Activity of ZW25
Anti-Tumor Activity of ZW25 Figure: Percentage Change from Baseline Part 1in Sum2: and of10 Diameters mg/kgofQW Target andLesions 20 mg/kg Q2W Patients 60 Disease Response Per Investigator Assessment (using RECIST 1.1) Part 1 and 2: 10 mg/kg QW and 20 mg/kg Q2W Patients Biliary CRC GEA All others To
Slide 6: Time on Treatment for Response-evaluable Patients
Time on Treatment for Response-evaluable Patients Part 1 and 2 Patients: 10 mg/kg QW and 20 mg/kg Q2W Patients • Overall median progression-free survival: 5.5 months (95% CI 3.6, 6.4) Part 1 and 2: 10 m 60 T PR cPR cPR cPR cPR cPR cPR cPR PD PR cPR cPR cPR PD SD SD PR cPR PR cPR cPR PD PR cPR PD T S
Slide 7: Conclusions
Conclusions • ZW25 is well tolerated with promising single-agent anti-tumor activity in patients with advanced HER2-expressing cancers that have progressed after standard of care therapies (median of 3 prior lines of therapy), including HER2-targeted agents • ZW25 has the potential to provide a cyto
Slide 8: Acknowledgment
Acknowledgment We sincerely thank all patients and their families. Thanks to all investigators and clinical trial personnel: Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, US; USC